<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01715311</url>
  </required_header>
  <id_info>
    <org_study_id>CQAB149B2425</org_study_id>
    <secondary_id>2012-001536-59</secondary_id>
    <nct_id>NCT01715311</nct_id>
  </id_info>
  <brief_title>Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control</brief_title>
  <acronym>INITIATE</acronym>
  <official_title>A Randomized, Double-blind Placebo-controlled Study to Compare the Efficacy of Indacaterol With That of Placebo in Patients With COPD Who Have Not Previously Received Maintenance COPD Medication, Using Blinded Tiotropium as Active Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the efficacy of indacaterol versus placebo (i.e., rescue medication
      only) and tiotropium in patients with Chronic Obstructive Pulmonary Disease (COPD) who have
      not received maintenance COPD medication for at least 12 months prior to entry (described
      hereafter as &quot;maintenance naïve&quot;, see inclusion criteria).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose is to provide efficacy data comparing the long-acting beta-2 agonist,
      indacaterol, with short-acting rescue therapy in maintenance-naive patients belonging to GOLD
      2011 Groups A and B.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    withdrawn prior to patient recruitment
  </why_stopped>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy comparison of indacaterol to placebo</measure>
    <time_frame>12 weeks</time_frame>
    <description>Efficacy comparison of indacaterol to placebo (once daily treatment) by measuring Trough Forced Expiratory Volume in one second 24 hour postdose after 12 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>St George's Respiratory Questionnaire for COPD (SGRQ- C) total score comparison between treatments</measure>
    <time_frame>12 weeks</time_frame>
    <description>Effects comparison of indacaterol to placebo in terms of the patient-centric measurement St George's Respiratory Questionnaire for COPD (SGRQ- C) total score after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Forced Expiratory Volume in one second between indacaterol and tiotropium groups</measure>
    <time_frame>12 weeks</time_frame>
    <description>Comparison of indacaterol to tiotropium using Trough Forced Expiratory Volume in one second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St George's Respiratory Questionnaire for COPD total score comparison between treatments</measure>
    <time_frame>12 weeks</time_frame>
    <description>Effects comparison of indacaterol to tiotropium in terms of St George's Respiratory Questionnaire for COPD (SGRQ- C) total score after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and serious adverse events for all treatment groups</measure>
    <time_frame>week 12</time_frame>
    <description>All adverse events will be reported</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Indacaterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indacaterol once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for indacaterol and placebo for tiotropium once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol</intervention_name>
    <description>Indacaterol once daily via single-dose dry powder inhaler</description>
    <arm_group_label>Indacaterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to tiotropium</intervention_name>
    <description>Placebo to tiotropium capsules for inhalation once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tiotropium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Tiotropium capsules for inhalation once daily</description>
    <arm_group_label>Tiotropium</arm_group_label>
    <other_name>Tiotropium 18 mcg od via single-dose dry powder inhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to indacaterol</intervention_name>
    <description>Placebo to indacaterol capsules for inhalation once daily</description>
    <arm_group_label>Indacaterol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stable Chronic Obstructive Pulmonary Disease (COPD) Groups A or B
             according to GOLD 2011.

          -  Patients with a post-bronchodilator Forced Expiratory Volume in one second (FEV1) ≥50%
             and &lt;80% of the predicted normal, and post-bronchodilator FEV1/ Forced Vital Capacity
             (FVC) &lt; 0.7

          -  Patients with no record of receipt of maintenance medication for COPD.

          -  Patients with a mMRC dyspnea score ≥1 at Visit 2.

          -  Current or ex-smokers who have a smoking history of at least 10 pack years.

        Exclusion Criteria:

          -  Patients who have not achieved acceptable spirometry results at run-in, in accordance
             with American Thoracic Society (ATS) / European Respiratory Society (ERS) criteria for
             acceptability and repeatability.

          -  Patients who have had 2 or more COPD exacerbations that required treatment with
             antibiotics, systemic steroids (oral or intravenous) or hospitalization in the 12
             months prior to Visit 1.

          -  Patients who have had a respiratory tract infection.

          -  Patients requiring long-term oxygen therapy (&gt;12 hours a day) on a daily basis.

          -  Patients with a) any history of asthma, or b) onset of respiratory symptoms prior to
             age 40 years.

          -  Patients with allergic rhinitis who use a H1-antagonist or intra-nasal corticosteroids
             intermittently. Treatment with a stable dose is permitted.

          -  Patients with concomitant pulmonary disease (e.g., lung fibrosis, sarcoidosis,
             interstitial lung disorder, pulmonary hypertension) or active pulmonary tuberculosis

          -  Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2012</study_first_submitted>
  <study_first_submitted_qc>October 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2012</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Chronic obstructive pulmonary disease</keyword>
  <keyword>indacaterol</keyword>
  <keyword>tiotropium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

